Close

Theravance Biopharma (TBPH) Announces Dosing of First Patient in TD-1473 Phase 1b as Ulcerative Colitis Treatment

Go back to Theravance Biopharma (TBPH) Announces Dosing of First Patient in TD-1473 Phase 1b as Ulcerative Colitis Treatment

Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis

October 4, 2016 8:05 AM EDT

DUBLIN, IRELAND -- (Marketwired) -- 10/04/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 1b clinical trial of TD-1473 in patients with moderate to severe ulcerative colitis. TD-1473 is a novel, potent, orally administered and intestinally restricted pan-Janus kinase (JAK) inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases. Importantly, TD-1473 is specifically designed to act directly at the site of inflammation in the intestinal wall with minimal systemic exposure.

The Phase 1b trial is a multi-center, randomized,... More